The Bardet-Biedl Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Bardet-Biedl Syndrome: An Overview
Bardet–Biedl syndrome (BBS) is an autosomal recessive inherited condition that affects many parts of the body. People with Bardet-Biedl Syndrome have progressive visual impairment due to cone-rod dystrophy, decreased function of the male gonads (hypogonadism), kidney abnormalities, extra fingers or toes (polydactyly), truncal obesity, and learning difficulties.
Bardet-Biedl Syndrome Market Key Facts
As per ORPHANET, the prevalence of Bardet–Biedl syndrome in Europe is estimated at between 1/125,000 and 1/175,000.
As per the study by Hirano et al. (2015), the prevalence of Bardet–Biedl syndrome is lower in the United Kingdom (1:125,000). In Western countries, Bardet–Biedl syndrome is often reported but remains undiagnosed in many patients until later in life.
As per Genetic Home Reference NIH; “In most of North America and Europe, Bardet–Biedl syndrome has a prevalence of 1 in 140,000 to 1 in 160,000 newborns.”
Get FREE sample copy at: Bardet-Biedl Syndrome Therapeutics Market
Key Benefits of Bardet-Biedl Syndrome Market Report
The report provides an in-depth analysis of Bardet-Biedl Syndrome Market Size and Share till 2030 in the seven major markets.
The report will help in developing business strategies by understanding the Bardet-Biedl Syndrome Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.
It covers Bardet-Biedl Syndrome current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
The report provides a detailed assessment of the Bardet-Biedl Syndrome market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
As per the DelveInsight, the dynamics of the Bardet–Biedl Syndrome market is anticipated to change in the coming years owing to the approval of the emerging therapy.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Bardet-Biedl Syndrome market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Bardet-Biedl Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Bardet-Biedl Syndrome Epidemiology
The epidemiology section covers insights about the historical and current Bardet-Biedl Syndrome patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Bardet-Biedl Syndrome Epidemiology Segmentation
Treatment Eligible Patients
Bardet-Biedl Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bardet-Biedl Syndrome market or expected to get launched in the market during the study period. The analysis covers Bardet-Biedl Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Bardet-Biedl Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Currently, Rhythm Pharmaceutical is working on Setmelanotide for the treatment of Bardet–Biedl Syndrome. Setmelanotide is an investigational melanocortin-4 receptor (MC4R) agonist in clinical development for the treatment of rare genetic disorders of obesity. It is currently in phase III clinical trial; designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in patients with Bardet Biedl syndrome (BBS) or Alström syndrome (AS).
Request for Sample @ Bardet-Biedl Syndrome Emerging Therapies and Key Companies
Table of Content
1. Key Insights
2. Executive Summary
3. Bardet-Biedl Syndrome Competitive Intelligence Analysis
4. Bardet-Biedl Syndrome Market Overview at a Glance
5. Bardet-Biedl Syndrome Disease Background and Overview
6. Bardet-Biedl Syndrome Patient Journey
7. Bardet-Biedl Syndrome Epidemiology and Patient Population
8. Bardet-Biedl Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Bardet-Biedl Syndrome Unmet Needs
10. Key Endpoints of Bardet-Biedl Syndrome Treatment
11. Bardet-Biedl Syndrome Marketed Products
12. Bardet-Biedl Syndrome Emerging Therapies
13. Bardet-Biedl Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Bardet-Biedl Syndrome Market Outlook (7 major markets)
16. Bardet-Biedl Syndrome Access and Reimbursement Overview
17. KOL Views on the Bardet-Biedl Syndrome Market.
18. Bardet-Biedl Syndrome Market Drivers
19. Bardet-Biedl Syndrome Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/bardet-biedl-syndrome-market
Learning Disability Treatment Landscape
Globally, a significant proportion of the population is affected by various forms of learning disabilities. As a result of the genetic and neurobiological factors, the affected person struggles to understand new or complex information and also faces difficulties in learning new skills, which hamper their growth and personal development. As of now, there is no medication for learning disabilities, however, digital assistive technologies are playing a crucial role to support the individual by enhancing their functional capacity. Read More: Learning Disability Treatment
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States